InsiderTrades

Form 4 for EWTX Edgewise Therapeutics, Inc.

Accepted 2024-05-03 00:00:00 ET · period of report 2024-05-01 · accession 0001562180-24-003825 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-05-03 2024-05-01 EWTX KOCH KEVIN Pres, CEO, Dir M - OptEx $0.00 +10.4K 17.6K +144% $0
D 2024-05-03 2024-05-02 EWTX KOCH KEVIN Pres, CEO, Dir S - Sale+OE $18.91 -3,152 14.5K -18% -$59.6K
D 2024-05-03 2024-05-01 EWTX KOCH KEVIN Pres, CEO, Dir M - OptEx $0.00 -10.4K 10.4K -50% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-05-01 M A 10,417 $0.00 17,630 D — —
2 Common Common Stock 2024-05-02 S D 3,152 $18.91 14,478 D — — (F2) The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $18.68 to $19.12, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3 Derivative Restricted Stock Units 2024-05-01 M D 10,417 $0.00 10,417 D $0.00 · — to 2032-05-01 10,417 Common Stock (F7) RSUs granted to the reporting person which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023.